Diabetes is a hugely lucrative business and better mousetraps quickly garner considerable attention. With the first commercial continuous glucose monitor (DexCom (Nasdaq:DXCM)) and the first disposable insulin pump (Insulet (Nasdaq:PODD)), these two companies have clearly stepped up as innovators in the field. DexCom would seem to have the brighter future at this point, as Insulet continues to burn through cash and has not managed to grab a sustainable level of market share.
There are no replies in this thread yet. Be the first to post a reply below: